Thoracic mesenchymal malignant tumors and programed cell death ligand‐1 status: Clinicopathologic and prognostic analysis of eight pulmonary sarcomatoid carcinomas and eight malignant mesotheliomas

Abstract Background The current study aimed to evaluate the significance of clinicopathological factors, particularly the immunohistochemistry of programed cell death ligand‐1 (PD‐L1), in eight cases each of pulmonary sarcomatoid carcinoma (PSC) and malignant pleural mesothelioma (MPM) at our hospit...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Kanji Otsubo, Hiroki Sakai, Hiroyuki Kimura, Tomoyuki Miyazawa, Hideki Marushima, Koji Kojima, Naoki Furuya, Masamichi Mineshita, Motohiro Chosokabe, Junki Koike, Hisashi Saji
Formato:	article
Lenguaje:	EN
Publicado:	Wiley 2021
Materias:	immune checkpoint inhibitor malignant pulmonary methotelioma programed cell death ligand‐1 pulmonary sarcomatoid carcinoma Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/7c341e2b3c4344559912d9d7076e951e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:7c341e2b3c4344559912d9d7076e951e
record_format	dspace
spelling	oai:doaj.org-article:7c341e2b3c4344559912d9d7076e951e2021-12-02T02:34:55ZThoracic mesenchymal malignant tumors and programed cell death ligand‐1 status: Clinicopathologic and prognostic analysis of eight pulmonary sarcomatoid carcinomas and eight malignant mesotheliomas1759-77141759-770610.1111/1759-7714.14177https://doaj.org/article/7c341e2b3c4344559912d9d7076e951e2021-12-01T00:00:00Zhttps://doi.org/10.1111/1759-7714.14177https://doaj.org/toc/1759-7706https://doaj.org/toc/1759-7714Abstract Background The current study aimed to evaluate the significance of clinicopathological factors, particularly the immunohistochemistry of programed cell death ligand‐1 (PD‐L1), in eight cases each of pulmonary sarcomatoid carcinoma (PSC) and malignant pleural mesothelioma (MPM) at our hospital. Methods From January 2004 to December 2020, a total of 16 consecutive patients (eight with PSC and eight with MPM diagnosed via surgical resection or biopsy) were included in this study. After retrospectively reviewing the patient characteristics, the associations between PD‐L1 status and age, sex, stage, histological type, and prognosis were investigated. Results PD‐L1‐positive staining was observed in four (50%) PSC cases and one (12.5%) MPM case. Among the four PD‐L1‐positive PSC cases, two showed high PD‐L1 expression in the vimentin‐positive sarcomatoid compartment. Moreover, among those with PSC, two survived for about 10 years, whereas the others died within 5 years. No clear correlation was found between PD‐L1 expression and prognosis. Among the patients with MPM, four survived for more than 2 years, with the longest being 9 years. Among MPM cases who received nivolumab, one patient with positive PD‐L1 staining in the sarcomatoid survived, whereas the other with negative PD‐L1 staining did not. Conclusion The present study showed that sarcomatoid carcinoma had a higher PD‐L1 expression compared to non‐small‐cell lung cancer and that both PSC and MPM tended to exhibit PD‐L1 positivity in the sarcomatoid compartment. Moreover, while immune checkpoint inhibitors may somewhat prolong the prognosis of both tumors, further studies with a larger cohort are necessary to confirm our results.Kanji OtsuboHiroki SakaiHiroyuki KimuraTomoyuki MiyazawaHideki MarushimaKoji KojimaNaoki FuruyaMasamichi MineshitaMotohiro ChosokabeJunki KoikeHisashi SajiWileyarticleimmune checkpoint inhibitormalignant pulmonary methoteliomaprogramed cell death ligand‐1pulmonary sarcomatoid carcinomaNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENThoracic Cancer, Vol 12, Iss 23, Pp 3169-3176 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	immune checkpoint inhibitor malignant pulmonary methotelioma programed cell death ligand‐1 pulmonary sarcomatoid carcinoma Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	immune checkpoint inhibitor malignant pulmonary methotelioma programed cell death ligand‐1 pulmonary sarcomatoid carcinoma Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Kanji Otsubo Hiroki Sakai Hiroyuki Kimura Tomoyuki Miyazawa Hideki Marushima Koji Kojima Naoki Furuya Masamichi Mineshita Motohiro Chosokabe Junki Koike Hisashi Saji Thoracic mesenchymal malignant tumors and programed cell death ligand‐1 status: Clinicopathologic and prognostic analysis of eight pulmonary sarcomatoid carcinomas and eight malignant mesotheliomas
description	Abstract Background The current study aimed to evaluate the significance of clinicopathological factors, particularly the immunohistochemistry of programed cell death ligand‐1 (PD‐L1), in eight cases each of pulmonary sarcomatoid carcinoma (PSC) and malignant pleural mesothelioma (MPM) at our hospital. Methods From January 2004 to December 2020, a total of 16 consecutive patients (eight with PSC and eight with MPM diagnosed via surgical resection or biopsy) were included in this study. After retrospectively reviewing the patient characteristics, the associations between PD‐L1 status and age, sex, stage, histological type, and prognosis were investigated. Results PD‐L1‐positive staining was observed in four (50%) PSC cases and one (12.5%) MPM case. Among the four PD‐L1‐positive PSC cases, two showed high PD‐L1 expression in the vimentin‐positive sarcomatoid compartment. Moreover, among those with PSC, two survived for about 10 years, whereas the others died within 5 years. No clear correlation was found between PD‐L1 expression and prognosis. Among the patients with MPM, four survived for more than 2 years, with the longest being 9 years. Among MPM cases who received nivolumab, one patient with positive PD‐L1 staining in the sarcomatoid survived, whereas the other with negative PD‐L1 staining did not. Conclusion The present study showed that sarcomatoid carcinoma had a higher PD‐L1 expression compared to non‐small‐cell lung cancer and that both PSC and MPM tended to exhibit PD‐L1 positivity in the sarcomatoid compartment. Moreover, while immune checkpoint inhibitors may somewhat prolong the prognosis of both tumors, further studies with a larger cohort are necessary to confirm our results.
format	article
author	Kanji Otsubo Hiroki Sakai Hiroyuki Kimura Tomoyuki Miyazawa Hideki Marushima Koji Kojima Naoki Furuya Masamichi Mineshita Motohiro Chosokabe Junki Koike Hisashi Saji
author_facet	Kanji Otsubo Hiroki Sakai Hiroyuki Kimura Tomoyuki Miyazawa Hideki Marushima Koji Kojima Naoki Furuya Masamichi Mineshita Motohiro Chosokabe Junki Koike Hisashi Saji
author_sort	Kanji Otsubo
title	Thoracic mesenchymal malignant tumors and programed cell death ligand‐1 status: Clinicopathologic and prognostic analysis of eight pulmonary sarcomatoid carcinomas and eight malignant mesotheliomas
title_short	Thoracic mesenchymal malignant tumors and programed cell death ligand‐1 status: Clinicopathologic and prognostic analysis of eight pulmonary sarcomatoid carcinomas and eight malignant mesotheliomas
title_full	Thoracic mesenchymal malignant tumors and programed cell death ligand‐1 status: Clinicopathologic and prognostic analysis of eight pulmonary sarcomatoid carcinomas and eight malignant mesotheliomas
title_fullStr	Thoracic mesenchymal malignant tumors and programed cell death ligand‐1 status: Clinicopathologic and prognostic analysis of eight pulmonary sarcomatoid carcinomas and eight malignant mesotheliomas
title_full_unstemmed	Thoracic mesenchymal malignant tumors and programed cell death ligand‐1 status: Clinicopathologic and prognostic analysis of eight pulmonary sarcomatoid carcinomas and eight malignant mesotheliomas
title_sort	thoracic mesenchymal malignant tumors and programed cell death ligand‐1 status: clinicopathologic and prognostic analysis of eight pulmonary sarcomatoid carcinomas and eight malignant mesotheliomas
publisher	Wiley
publishDate	2021
url	https://doaj.org/article/7c341e2b3c4344559912d9d7076e951e
work_keys_str_mv	AT kanjiotsubo thoracicmesenchymalmalignanttumorsandprogramedcelldeathligand1statusclinicopathologicandprognosticanalysisofeightpulmonarysarcomatoidcarcinomasandeightmalignantmesotheliomas AT hirokisakai thoracicmesenchymalmalignanttumorsandprogramedcelldeathligand1statusclinicopathologicandprognosticanalysisofeightpulmonarysarcomatoidcarcinomasandeightmalignantmesotheliomas AT hiroyukikimura thoracicmesenchymalmalignanttumorsandprogramedcelldeathligand1statusclinicopathologicandprognosticanalysisofeightpulmonarysarcomatoidcarcinomasandeightmalignantmesotheliomas AT tomoyukimiyazawa thoracicmesenchymalmalignanttumorsandprogramedcelldeathligand1statusclinicopathologicandprognosticanalysisofeightpulmonarysarcomatoidcarcinomasandeightmalignantmesotheliomas AT hidekimarushima thoracicmesenchymalmalignanttumorsandprogramedcelldeathligand1statusclinicopathologicandprognosticanalysisofeightpulmonarysarcomatoidcarcinomasandeightmalignantmesotheliomas AT kojikojima thoracicmesenchymalmalignanttumorsandprogramedcelldeathligand1statusclinicopathologicandprognosticanalysisofeightpulmonarysarcomatoidcarcinomasandeightmalignantmesotheliomas AT naokifuruya thoracicmesenchymalmalignanttumorsandprogramedcelldeathligand1statusclinicopathologicandprognosticanalysisofeightpulmonarysarcomatoidcarcinomasandeightmalignantmesotheliomas AT masamichimineshita thoracicmesenchymalmalignanttumorsandprogramedcelldeathligand1statusclinicopathologicandprognosticanalysisofeightpulmonarysarcomatoidcarcinomasandeightmalignantmesotheliomas AT motohirochosokabe thoracicmesenchymalmalignanttumorsandprogramedcelldeathligand1statusclinicopathologicandprognosticanalysisofeightpulmonarysarcomatoidcarcinomasandeightmalignantmesotheliomas AT junkikoike thoracicmesenchymalmalignanttumorsandprogramedcelldeathligand1statusclinicopathologicandprognosticanalysisofeightpulmonarysarcomatoidcarcinomasandeightmalignantmesotheliomas AT hisashisaji thoracicmesenchymalmalignanttumorsandprogramedcelldeathligand1statusclinicopathologicandprognosticanalysisofeightpulmonarysarcomatoidcarcinomasandeightmalignantmesotheliomas
_version_	1718402359217881088

Thoracic mesenchymal malignant tumors and programed cell death ligand‐1 status: Clinicopathologic and prognostic analysis of eight pulmonary sarcomatoid carcinomas and eight malignant mesotheliomas

Ejemplares similares